NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

learningcurve2020,

You might consider posting less frequently and more thoughtfully. Your sophomoric approach is transparent and counterproductive to your objectives—you’re only demonstrating that the prospective value of NWBO is likely vast. The incessant random innuendo spaghetti that you throw at the wall signals value! If a sharp rise in the price were not on the horizon, you would not commit so many hours to publishing thoughtless mud on a message board throughout a holiday weekend. Thanks for the indicator!! 😉

Ironically however, you do sometimes post a real gem💎! The JCI publication set me on a path of exploration that I had previously overlooked. Now, I can appreciate more fully how the combo implications are potentially significant and game-changing. I am not an oncologist, but I find this technology fascinating as a platform…

Soon after LC posted the link to JCI, the Merck PR was published about the Daiichi Sankyo deal, and then I went back to reread the article again and I watched some videos of Dr. Liau’s discussions on the topic of combo therapy…

✅ DCVax-L is efficacious (see JAMA Oncology).

✅ DCVax-L + PD1 is perhaps far more efficacious than DCVax-L as a monotherapy (see interim survival data).

⭐️ DCVax-L technology + PD1 technology + CFS-1R technology or ADC technology could be yet another breakthrough … The P3 that was published in JAMA Oncology looks like only the tip of an enormous iceberg!

Perhaps without realizing it, I think LC may have actually dropped the mic after announcing the JCI publication!

Combo is King!

The field of cell-based therapy is evolving rapidly and the DCVax-L platform might be a key component to unlocking the efficacy of more than one class of drugs!

Thanks in part to all of LC’s posts on this message board, I have arrived at the view that each existing, emerging, or recently commercialized drug class in the field of oncology represents another potential opportunity to discover an efficacious combo with the DCVax-L platform! PD1 blockade is only one excellent example that bodes well for further successful combos.

https://www.cell.com/trends/cancer/fulltext/S2405-8033(23)00005-5

https://thehealthcaretechnologyreport.com/merck-and-daiichi-sankyo-enter-landmark-5-5-billion-partnership/

https://www.jci.org/articles/view/169314



The Nobel Prize was a harbinger of the novel DCVax-L cell-based platform technology!

https://www.livescience.com/16354-nobel-prize-medicine-2011-immune-research.html




Dr. Steinman’s work lives on at UCLA!

https://www.uclahealth.org/news/brain-cancer-discovery-clinical-trials